Compare MARA & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MARA | RYTM |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.8B |
| IPO Year | 2010 | 2017 |
| Metric | MARA | RYTM |
|---|---|---|
| Price | $14.82 | $107.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $17.85 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 39.0M | 814.7K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $907,093,000.00 | N/A |
| Revenue This Year | N/A | $55.34 |
| Revenue Next Year | $13.31 | $86.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 38.20 | N/A |
| 52 Week Low | $6.66 | $62.29 |
| 52 Week High | $23.45 | $122.20 |
| Indicator | MARA | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 57.97 | 75.44 |
| Support Level | $11.68 | $98.30 |
| Resistance Level | $15.32 | $113.03 |
| Average True Range (ATR) | 1.30 | 5.00 |
| MACD | -0.02 | 2.22 |
| Stochastic Oscillator | 59.39 | 86.42 |
MARA Holdings Inc leverages digital asset computing to support the energy transformation. It secures the blockchain ledger and supports the energy transformation by converting clean, stranded, or underutilized energy into economic value. The company also offers technology solutions to optimize data center operations, including next-generation liquid immersion cooling and firmware for Bitcoin miners. It is focused on computing for, acquiring, and holding digital assets as a long-term investment.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.